Humacyte Inc (NASDAQ:HUMA) price on current trading day, rose 5.75% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.31.
A look at the stock’s price movement, the close in the last trading session was $3.13, moving within a range at $3.0822 and $3.31. The beta value (5-Year monthly) was 1.36. Turning to its 52-week performance, $9.97 and $2.75 were the 52-week high and 52-week low respectively. Overall, HUMA moved -11.73% over the past month.
Humacyte Inc’s market cap currently stands at around $425.89 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-19.
Turning to the stock’s technical picture we see that short term indicators suggest on average that HUMA is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 1 recommend HUMA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
HUMA’s current price about 4.49% and -14.95% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 48.18, while 7-day volatility ratio is 8.84% and 9.35% in the 30-day chart. Further, Humacyte Inc (HUMA) has a beta value of 1.36, and an average true range (ATR) of 0.29. Analysts have given the company’s stock an average 52-week price target of $8, forecast between a low of $6 and high of $10. Looking at the price targets, the low is -81.27% off current price level while to achieve the yearly target high, price needs to move -202.11%. Nonetheless, investors will most likely welcome a -141.69% jump to $8 which is the analysts’ median price.
If we refocus on Humacyte Inc (NASDAQ:HUMA), historical trading data shows that trading volumes averaged 2.12 over the past 10 days and 4.07 million over the past 3 months. The company’s latest data on shares outstanding shows there are 119.84 million shares.
The 18.87% of Humacyte Inc’s shares are in the hands of company insiders while institutional holders own 33.28% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 25.48 million on 2025-02-28, giving us a short ratio of 13.45. The data shows that as of 2025-02-28 short interest in Humacyte Inc (HUMA) stood at 2551.0 of shares outstanding, with shares short rising to 24.04 million registered in 2025-01-31. Current price change has pushed the stock -34.46% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the HUMA stock continues to rise going into the next quarter.
